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LeprosyIt is widely accepted that tumor necrosis factor alpha (TNF-α) plays a critical role in the development of
tissue and nerve damage in leprosy and during the reactional episodes of acute inﬂammation. Thalidomide
(N-α-phthalimidoglutarimide), a drug used to treat leprosy reaction, modulates immune response, inhibits
inﬂammation and NF-κB activity. Here we investigated whether thalidomide inhibits NF-κB activation induced
by Mycobacterium leprae, p38 and ERK1/2 MAPK activation. EMSA and supershift assays were performed
to investigate NF-κB activation in response to M. leprae and its modulation following in vitro treatment
with thalidomide. Luciferase assay was assayed in transfected THP-1 cells to determine NF-κB transcriptional
activity. Flow cytometry and immunoﬂuorescence were used to investigate p65 accumulation in the nucleus.
Immunoblotting was used to investigate p38 and ERK1/2 phosphorylation. Following activation of PBMC and
monocytes with M. leprae, the formation and nuclear localization of NF-κB complexes composed mainly of
p65/p50 and p50/p50 dimers was observed. Induction of NF-κB activation and DNA binding activity was
inhibited by thalidomide. The drug also reduced M. leprae-induced TNF-α production and inhibited p38
and ERK1/2 activation. Deﬁnition of the activation mechanisms in cells stimulated with M. leprae can lead
to the development of new therapy applications to modulate NF-κB activation and to control the inﬂamma-
tory manifestations due to enhanced TNF-α response as observed in leprosy and in leprosy reactions.ldo Cruz Foundation, Av. Brasil,
l. Tel./fax: +55 21 2270 9997.
io).
vier OA license.© 2011 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Leprosy is a chronic infectious disease caused by Mycobacterium
leprae that affects the skin and peripheral nerves. The disease presents
a clinical spectrum that correlates with the immune response of the
host to the pathogen (Ridley and Jopling, 1966). It is widely accepted
that tumor necrosis factor alpha (TNF-α) plays a critical role in the
development of tissue and nerve damage in leprosy and in the path-
ogenesis of the episodes of acute inﬂammatory reaction (reversal re-
action, RR, and erythema nodosum leprosum, ENL) (Kahawita and
Lockwood, 2008; Sarno et al., 1991). These episodes may occur during
the chronic course of the disease and are treated either with steroids
and/or thalidomide. The clinical beneﬁts of thalidomide in ENL have
been attributed to its ability to inhibit TNF-α secretion both in vitroand in vivo (Sampaio et al., 1991, 1993), among others (Raﬁee et al.,
2010; Teo et al., 2002).
Nuclear factor-κB (NF-κB) constitutes a group of dimeric tran-
scription factors composed of various combinations of members of
the NF-κB/Rel family. NF-κB proteins are usually found in the cyto-
plasm in association with inhibitory proteins (inhibitory κB factors
or simply IκBs). Degradation of IκBs allows NF-κB to translocate to
the nucleus, binds to DNA binding sites, and regulates the transcrip-
tion of a large number of genes including cytokines, chemokines,
and antimicrobial peptides (Li and Verma, 2002). Mycobacteria and
their cell wall components, such as lipoarabinomannan, have been
described to induce NF-κB nuclear translocation (Means et al.,
2001) and MAP kinase activation, as important events for both cyto-
kine production and cell activation. In our previous work we showed
thatM. leprae also induces activation of NF-κB complexes in a human
Schwannoma cell line (Pereira et al., 2005).
Thalidomide (N-α-phthalimidoglutarimide) is a known anti-
angiogenic, anti-tumor, and antiproliferative agent, widely used for
the treatment of several immunological disorders, mainly leprosy
reaction (ENL) and cancer (Erlinger, 2010; Sampaio et al., 1993;
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cytokines while its TNF-α modulating property seems to be great-
ly related to drug activity (De Sanctis et al., 2010). Thalidomide in-
hibits TNF-α via enhanced degradation of the TNF mRNA (Kim
et al., 2004; Moreira et al., 1993). In addition, thalidomide has
broad activity with a clear effect on the inﬂammatory cascade in-
cluding modulation of p38 MAPK (Bartlett et al., 2004; Noman et
al., 2009) and NF-κB signaling pathway in response to differentN
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In the present study, we sought to detail how thalidomide modu-
lates M. leprae-induced response in vitro as it can correlate to the im-
provement in patient clinical responses. We demonstrate that
thalidomide suppresses NF-κB transcriptional activity, DNA binding
activity and activation induced by M. leprae in primary human cells
and consequently leading to reduced cytokine production. Moreover,B
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Fig. 2. Immunoﬂuorescence staining and confocal microscopy show translocation of
NF-κB p65 subunit to the nucleus in monocyte cultures after stimulation withM. leprae
(lower panel, MOI 20) as opposed to the nonstimulated wells (upper panel). Visualiza-
tion of cells was carried out by confocal microscopy using a 40× oil immersion objec-
tive and a 2× zoom magniﬁcation. One experiment out of four is presented.
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by the mycobacteria.
2. Material and methods
2.1. Studied population
A total of 13 leprosy patients (11 males, 2 females) who attended
the Leprosy Out-Patient Unit, Leprosy Laboratory, Oswaldo Cruz Foun-
dation (Rio de Janeiro, Brazil) were enrolled into the study. Patients
were diagnosed according to Ridley and Jopling classiﬁcation (1966),
were all multibacillary (bacillary index N0), andwere treatedwithmul-
tidrug therapy as recommended by the World Health Organization.
Healthy donors (n=5) from the Hemotherapy Unit, Clementino Fraga
Filho Hospital, Federal University of Rio de Janeiro were also included.
The study was approved by the Ethical Committee of FIOCRUZ and fol-
lowing informed consent, blood was withdrawn from all individuals
and experiments performed as described below.
2.2. Cell isolation and culture condition
Peripheral bloodmononuclear cells (PBMC)were isolated from hep-
arinized venous blood under endotoxin free conditions through Ficoll-
Hypaque (Pharmacia Fine Chemicals, Piscataway, NJ) density centrifu-
gation. PBMC were suspended at 106 cells/ml in RPMI 1640 medium
supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin,
2 mM L-glutamine, 10% FCS (GibcoBRL, Gaithersburg,MD), subsequent-
ly cultured in 24-well plates (Costar Corporation, Cambridge, MA), at
37 °C for 2 h, when cultures were washed for removal of non-adherent
cells. For in vitro stimulation, wholeM. leprae irradiated (2×109 bacte-
ria/ml), provided by Dr. P. Brennan (Microbiology Department, Colora-
do State University, Fort Collins, CO), and lipopolysaccharide (LPS) from
Salmonella Minnesota Re 595 (Sigma Chemical Co., St. Louis, MO) were
used. In parallel experiments, thalidomide (25 μg/ml; Calbiochem, Cam-
bridge, MA) was added to the cultures 1 h prior to cell stimulation.
2.3. Electrophoretic mobility shift assay (EMSA) and supershift assay
PBMC (107 cells) were cultured in Teﬂon beakers (Thomas Scien-
tiﬁc, Swedesboro, NJ) and stimulated with M. leprae (multiplicity of
infection, MOI 2 or 20) or LPS (1 μg/ml) for 30 min. After the stimula-
tion period, cells were washed, nuclear protein extracts were
obtained and EMSA and supershift assays were performed as detailed
elsewhere (Pereira et al., 2005).
2.4. Detection of NF-κB translocation by ﬂow cytometry
Cultured monocytes or PBMC were stimulated with M. leprae (MOI
20) or TNF-α (1 μg/ml), and after 1 h, nuclei from the cellswere obtained
by using Pipes–Triton buffer (10 mMPipes, 0.1 MNaCl, 2 mMMgCl2 and
0.1% Triton X-100; Sigma). Nuclei samples were washed, stained
with anti-p65 monoclonal or isotype control antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA), subsequently incubated with FITC-
conjugated goat anti-mouse Ig antibody and counterstained with pro-
pidium iodide (1 mg/ml; Sigma) (Cognasse et al., 2003). In some exper-
iments, cells were treated with thalidomide, the NF-κB inhibitor SN50,
its non-active mutant, SN50m (18 μM; Calbiochem), or the proteasome
inhibitor MG132 (4 μM; Calbiochem) followed by mycobacteria stimu-
lation. For evaluation of NF-κB translocation, samples were analyzed
by ﬂow cytometry on a FACS Calibur (BD Biosciences, San Jose, CA). A
total of 104 events were recorded for each experimental condition.
2.5. Cytokine detection
For detection of TNF-α, culture supernatants were harvested 20–
24 h after cell stimulation and stored at −20 °C until use. Cytokinelevels were assayed by a commercial speciﬁc enzyme-linked immu-
nosorbent assay (ELISA) processed according to the manufacturer's
speciﬁcations (R&D Systems Inc., Minneapolis, MN). Detection limit
of the assay was 8 pg/ml.
2.6. Immunoﬂuorescence and confocal microscopy
Monocytes settled onto glass coverslips were stimulated with the
mycobacteria (MOI 20) for 1 h, washed and ﬁxed in paraformalde-
hyde 3.7%. Cells were permeabilized with PBS-0.5% Triton X-100, la-
beled with a primary antibody against phospho-p65 (Santa Cruz
Biotechnology), followed by incubation with the secondary antibody
(Chemicon International, Temecula, CA). Nuclei were stained with
DAPI and images were acquired on a Laser Scanning Confocal Micros-
copy LSM 510-META (Zeiss, Thornwood, NY).
2.7. Luciferase assay
To measure NF-kB transcriptional activity, THP-1 cells were co-
transfected using FUGENE 6 reagent (Roche, Madison, WI) with a
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of ﬁreﬂy luciferase reporter gene (750 ng IgK-IFNLUC, kindly provid-
ed by Dr. David Baltimore, Massachusetts Institute of Technology,
Cambridge) and a constitutive active reporter containing Renilla lu-
ciferase gene (250 ng pRLCMV plasmid; Promega, Madison, WI).
After 48 h, cultures were washed, medium was replaced and cells
stimulated withM. leprae or TNF-α, in the presence or absence of tha-
lidomide for 6 h. Cells were resuspended in lysis buffer and luciferase
activity evaluated using the dual luciferase assay (Promega), detected
in a luminometer TD-20/20 (Turner Designs, Sunnyvale, CA). Experi-
ments were done in triplicate and values normalized to Renilla activ-
ity. Data are expressed as fold increase of luciferase activity over the
nonstimulated samples.A
B
C
Fig. 3.M. leprae-induced NF-κB is linked to proteasome activity and TNF-α release. (A) Mono
stimulated with M. leprae (ML, MOI 20). Flow cytometry analysis for detection of nuclear p
as compared to the nonstimulated samples (NS); (B) TNF-α levels were evaluated in the 20
cytokine response in the stimulated cells; (C) Monocytes pre-incubated with the proteasome
p65 staining as above (MFI). Inhibition of proteasome activity interferes with M. leprae-indu2.8. Immunoblotting
ForWestern blot analysis, cell lysates were obtained from cultured
monocytes in cell lysis buffer (Cell Signaling Technology) containing
protease and phosphatase inhibitors (Calbiochem). Proteins (30 μg)
were resolved on a 12% SDS-polyacrylamide gel blotted onto nitrocel-
lulose membrane (Bio-Rad). The membranes were blocked with BSA
5% and 0.1% Tween, washed and incubated with the primary anti-
phospho-p38 or anti-pERK1/2 antibodies (1:1000 dilution; Cell Sig-
naling). Following washing, the blots were incubated for an addition-
al hour in horseradish peroxidase conjugated secondary antibody
(eBioscience, San Diego, CA), and the bands detected by an enhanced
chemiluminescence system (Amersham Biosciences, Piscataway, NJ).cytes were pre-incubated with the NF-κB inhibitor SN50 or its mutant SN50m and cells
65 subunit shows decreased mean ﬂuorescence intensity (MFI) in the stimulated cells
h culture supernatants. The NF-κB inhibitor but not its mutant signiﬁcantly abolished
inhibitor MG132 (MG) were stimulated with the mycobacteria and assayed for nuclear
ced NF-κB activation. Data are mean of 5 individual experiments (*Pb0.05; **Pb0.01).
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body (Cell Signaling).
2.9. Statistical analysis
Results are expressed as mean±standard error (S.E.M.). Statistical
analysis was performed by using one-way ANOVA test. Flow cytome-
try data were analyzed using a paired t test (InStat/Prism software;
GraphPad Software, San Diego, CA). Differences were signiﬁcant at
Pb0.05.
3. Results
3.1. M. leprae induces NF-κB nuclear translocation in primary human
cells in vitro
NF-κB activation was investigated through EMSA in freshly isolat-
ed PBMC obtained from leprosy patients (Fig. 1A) and healthy donors,
following in vitro stimulation withM. leprae. Enhanced NF-κB bindingA
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To characterize the protein composition of the NF-κB complex,
speciﬁc antibodies against the NF-κB subunits were used in the super-
shift assay. As observed in Fig. 1B, antibodies against p65 and p50
subunits led to slower migrating complexes in the gels. We observed
the formation and nuclear localization of NF-κB complexes composed
mainly of p65/p50 and p50/p50 dimers. Addition of anti-p50 anti-
body shifted both complexes in the cells stimulated either with M.
leprae or LPS, whereas antibody against the p65 protein shifted the
top complex only (Fig. 1B). Antibodies against p52 or c-Rel proteins
did not modify the pattern of complex migration (not shown).
We then evaluated NF-κB p65 nuclear translocation in adherent
patients' monocytes by ﬂow cytometry. Following p65 staining in iso-
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60.2±7.4 vs. 31.3±4%, respectively (Fig. 1D; Pb0.05). Confocal mi-
croscopy conﬁrmed, at a single cell level, the nuclear translocation
of the p65 protein triggered by the mycobacteria (Fig. 2).
3.2. Activation of NF-κB is essential for M. leprae-induced TNF-α
production
Initially, the ability of SN50 to impair NF-κB activation was con-
ﬁrmed in cultured monocytes from healthy donors and patients
(not shown). Cells pre-treated with SN50, but not the mutated pep-
tide SN50m, showed impaired p65 nuclear staining in response to
M. leprae (Fig. 3A; Pb0.05) as MFI returned to baseline levels when
in the presence of the inhibitor.
The involvement of NF-κB in M. leprae-induced TNF-α response
was then assayed in cells pre-incubated with SN50 and stimulated
with the mycobacteria for 20–24 h. TNF-α values (1150±44 pg/ml)
were signiﬁcantly lower (Pb0.001) in the presence of the NF-κB in-
hibitor (15±4.1 pg/ml), whereas addition of SN50m showed no ef-
fect (Fig. 3B).
Previous work demonstrated that inhibition of the proteasome in-
terfered with M. leprae-induced cytokine release (Fulco et al., 2007).
Therefore, in this study, we pre-incubated the cells with MG132 and
observed through ﬂow cytometry reduced p65 staining in the treated
mycobacteria stimulated wells (Fig. 3C; P=0.03).
3.3. Thalidomide (THAL) reduces NF-κB activation and the production of
TNF-α in vitro
To determine if THAL can interfere with NF-κB binding activity in-
duced by M. leprae, PBMC obtained from leprosy patients were stim-
ulated with the mycobacteria in the presence of the drug and assayedA
B
Fig. 5. NF-κB transcriptional activity. (A) Whole cell lysates were obtained from tran-
siently transfected THP-1 cells with a NF-κB luciferase reporter plasmid introduced
along with a Renilla luciferase expression plasmid, stimulated for 6 h with (A) M.
leprae, ML, or (B) TNF-α in the presence or absence of thalidomide and analyzed for
luciferase activity. Data aremean of 3 individual experiments; *Pb0.05. NS=nonstimulated
cells.by EMSA. Cultures pre-treated with thalidomide showed decreased
NF-κB nuclear translocation generated both in response to M. leprae
and LPS (Fig. 4A). Viability of the cells in culture was not affected by
thalidomide (not shown).
Analysis by ﬂow cytometry also showed enhanced nuclear p65
staining induced by M. leprae (MFI=27.9±4.4) and such response
was down-regulated (16±3.1; P=0.007) in the presence of THAL
to the levels observed in the unstimulated cells (Fig. 4B). Accordingly,
percentage of p65 labeled cells was diminished in the treated stimu-
lated cultures (67.2±6.9 vs. 45.9±6%, respectively; P=0.015). The
effect of thalidomide was also evident since the drug abrogated
NF-κB activation (% p65 positive) induced by TNF-α in PBMC from
healthy donors (Fig. 4C) or patients. As previously described, levels
of TNF-α induced by M. leprae in the 20 h cultures were reduced by
THAL (Fig. 4D; Pb0.01).P-ERK 1/2
ERK 1/2
NS THAL ML ML+THAL
0.0
0.5p
B
Fig. 6. Thalidomide modulates M. leprae-induced activation of p38 MAPK. Monocytes
from healthy donors were pre-treated with THAL (25 μg/ml) and stimulated with M.
leprae for 30 min. Phosphorylation of (A) p38 and (B) ERK1/2 was detected by immu-
noblotting with the speciﬁc antibodies as described in the Material and methods sec-
tion. Densitometry of one representative experiment is presented.
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cells with a luciferase reporter assay using a plasmid that contains
binding sites for NF-κB and a constitutively active Renilla plasmid
for normalization. In accordance to the above described results, stim-
ulation of THP-1 with M. leprae (Fig. 5A) or TNF-α induced (Fig. 5B)
NF-κB mediated response was repressed when cells were treated
with thalidomide.
3.4. Thalidomide treatment inhibits MAPK activation induced by M.
leprae
Previous studies have described that thalidomide inhibits the
phosphorylation of the MAPK pathway induced by LPS (Noman et
al., 2009). We then evaluated whether THAL interfered with the up-
stream pathways involved in the M. leprae-induced NF-κB response.
Analysis by immunoblotting revealed that phosphorylation of p38 ob-
served in monocytes isolated from healthy individuals (Fig. 6A) or
leprosy patients, and phosphorylation of ERK1/2 assayed 30 min
after stimulation with M. leprae (Fig. 6B) was inhibited by THAL.
4. Discussion
Accumulating evidence suggests that production of TNF-α in re-
sponse toM. leprae infection can contribute to the pathology of leprosy
(Hernandez et al., 2003; Kahawita and Lockwood, 2008; Scollard et al.,
2006). However, the intracellular mechanisms leading to mycobac-
teria-induced cytokine response are not yet fully characterized. Previous
results demonstrate that M. leprae triggers the TLR2 signaling pathway
(Krutzik et al., 2003) and as shown here, it enhances both the nuclear
translocation and the DNA binding activity of NF-κB p65/p50 and
p50/p50 complexes in primary human cells. Our results also reinforce
the involvement of NF-κB onM. leprae-induced TNF-α release in vitro.
The development of an inﬂammatory response is a key event dur-
ing mycobacterial infections. Several groups have reported activation
of NF-κB in response to both intact mycobacteria and mycobacterial
cell wall components (Lee and Schorey, 2005; Means et al., 2001),
macrophages infected with Mycobacterium smegmatis (Gutierrez et
al., 2008), and in cells from patients infected with M. tuberculosis
(Ameixa and Friedland, 2002). NF-κB activation seems to be essential
for mycobacterial killing since when NF-κB is blocked M. smegmatis
survived (Gutierrez et al., 2008). On the other hand, some studies
have described inhibition of NF-κB activation by M. tuberculosis com-
ponents (Pathak et al., 2005, 2007).
Here we demonstrate that M. leprae induces NF-κB activation in
primary human cells (PBMC and monocytes) and that thalidomide
can suppress mycobacteria-induced NF-κB in vitro. We found that
both homo and heterodimer forms of NF-κB were inhibited and led
to the reduced TNF-α response. Thalidomide also inhibited NF-κB ac-
tivation induced by TNF-α in Schwann cells (Pereira et al., 2005) and
in PBMC (Fig. 4) in vitro. Overall, the results support the ability of M.
leprae to induce TNF-α and NF-κB activation; TNF sustains NF-κB re-
sponse and thalidomide interferes in this positive feedback loop.
The ability of thalidomide to down-regulate M. leprae-induced
NF-κB activity poses a picture for the potent inhibitory effect this
drug has over controlling the inﬂammatory manifestations of leprosy.
Previous data showed that thalidomide also inhibited the complex
p50/p50 and abolishedM. leprae-induced gene transcriptional repres-
sion in a human Schwann cell line (Pereira et al., 2005). These results
suggest that the inhibitory effect of thalidomide over M. leprae stim-
ulation is not cell-type speciﬁc.
It has been suggested that the drug's ability to modulate gene ex-
pression through suppression of NF-κB might be related to the path-
way that is activated by the inducer (Majumdar et al., 2002). Recent
studies have described that thalidomide inhibits LPS-induced TNF-α
production and NF-κB activation in RAW 264.7 cells by preventingphosphorylation of IkBα and IkB kinases (IKK-α and -β), and via
down-regulation of MyD88 (Noman et al., 2009).
The ubiquitin–proteasome pathway controls various cellular pro-
cesses and modulates NF-κB regulation through proteolytic proces-
sing of NF-κB precursors, polyubiquitination, and degradation of the
inhibitory protein IkBα. We have also shown herein that inhibition
of proteasome reduces NF-κB activity in response to M. leprae, and
that this inhibition may impact into the lower induced cytokine
production as reported previously (Fulco et al., 2007). A recent
data suggest that the inhibition of NF-κB-dependent gene expres-
sion by bortezomib, a proteasome inhibitor, is gene speciﬁc and de-
pends on the subunit composition of NF-κB dimers recruited to
NF-κB-responsive promoters (Juvekar et al., 2011). More interest-
ingly, one recent study identiﬁed a thalidomide-binding protein,
cereblon (CRBN), as a primary target for thalidomide teratogenicity
and the drug inhibits its ubiquitin ligase activity (Ito et al., 2011).
It is clear that many pathways are to be involved in leprosy and
other diseases in which thalidomide is effective. Further experiments
are still necessary to clarify the molecular mechanisms by which tha-
lidomide modulates M. leprae-induced NF-κB.
Work by several groups has established that MAPKs play a critical
role in the pathogenesis of various malignancies. One recent work de-
scribed that M. leprae inhibited the phosphorylation of either p38 or
ERK1/2 in T cells (Dagur et al., 2010). We observed herein that M.
lepraewas able to increase activation of ERK1/2 and to a lesser extent
of p38 in primary human monocytes. Thalidomide was able to de-
crease the M. leprae-induced phosphorylation of both p38 and
ERK1/2 MAPKs, implying that the effect of thalidomide on NF-κB ac-
tivity and on TNF-α secretion might involve MAPKs deactivation.
Our data show that thalidomide inhibits both p38/ERK and NF-κB
activation in the stimulated cells. Deﬁnition of the mechanisms trig-
gered in human cells challenged with mycobacteria can lead to the
development of new therapy applications to control the inﬂammato-
ry manifestations as observed in leprosy and in leprosy reactions.
Conﬂict of interest
The authors declare no competing conﬂict of interest.
Acknowledgments
We are grateful to J.A.C. Nery and A.M. Sales, the Leprosy Outpatient
Unit, FIOCRUZ, to E.B. Oliveira and R. Teles for technical assistance, and
P.A. Manso for assistancewith the confocal experiments. This studywas
supported by IOC/FIOCRUZ, in part by CNPq Research Grant and CNPq
Fellowship Program, Brazil.
References
Ameixa, C., Friedland, J.S., 2002. Interleukin-8 secretion fromMycobacterium tuberculosis—
infected monocytes is regulated by protein tyrosine kinases but not ERK 1/2 or p38
mitogen-activated protein kinases. Infect. Immun. 70, 4743–4746.
Bartlett, J.B., Dredge, K., Dalgleish, A.G., 2004. The evolution of thalidomide and its IMiD
derivatives as anticancer agents. Nat. Rev. Cancer 4, 314–322.
Cognasse, F., Sabido, O., Béniguel, L., Genin, C., Garraud, O., 2003. A ﬂow cytometry
technique to study nuclear factor-kappa B (NFkappaB) translocation during
human B cell activation. Immunol. Lett. 90, 49–52.
Dagur, P.K., Sharma, B., Kumar, G., Khan, N.A., Katoch, V.M., Sengupta, U., Joshi, B., 2010.
Mycobacterial antigen(s) induce anergy by altering TCR- and TCR/CD28-induced
signaling events: insights into T-cell unresponsiveness in leprosy. Mol. Immunol.
47, 943–952.
De Sanctis, J.B., Mijares, M., Suárez, A., Compagnone, R., Garmendia, J., Moreno, D., Salazar-
Bookaman, M., 2010. Pharmacological properties of thalidomide and its analogues.
Rec. Pat. Inﬂamm. Allergy Drug Discov. 4, 144–148.
Erlinger, S., 2010. The thalidomide renaissance. Gastroenterol. Clin. Biol. 34, 426–428.
Fulco, T.O., Lopes, U.G., Sarno, E.N., Sampaio, E.P., Saliba, A.M., 2007. The proteasome
function is required for Mycobacterium leprae-induced apoptosis and cytokine se-
cretion. Immunol. Lett. 110, 82–85.
Gutierrez, M.G., Mishra, B.B., Jordao, L., Elliott, E., Anes, E., Grifﬁths, G., 2008. NFkappa B
activation controls phagolysosome fusion-mediated killing of mycobacteria by
macrophages. J. Immunol. 181, 2651–2663.
279M.O. Hernandez et al. / European Journal of Pharmacology 670 (2011) 272–279Hernandez, M.O., Neves, I., Sales, J.S., Carvalho, D.S., Sarno, E.N., Sampaio, E.P., 2003. In-
duction of apoptosis in monocytes byMycobacterium leprae in vitro: a possible role
for tumour necrosis factor-alpha. Immunology 109, 156–164.
Ito, T., Ando, H., Handa, H., 2011. Teratogenic effects of thalidomide: molecular mech-
anisms. Cell. Mol. Life Sci. 68, 1569–1579.
Juvekar, A., Manna, S., Ramaswami, S., Chang, T.P., Vu, H.Y., Ghosh, C.C., Celiker, M.Y.,
Vancurova, I., 2011. Bortezomib induces nuclear translocation of I{kappa}B{alpha}
resulting in gene-speciﬁc suppression of NF-{kappa}B-dependent transcription
and induction of apoptosis in CTCL. Mol. Cancer Res. 9, 183–194.
Kahawita, I.P., Lockwood, D.N., 2008. Towards understanding the pathology of erythe-
ma nodosum leprosum. Trans. R. Soc. Trop. Med. Hyg. 102, 329–337.
Keifer, J.A., Guttridge, D.C., Ashburner, B.P., Baldwin Jr., A.S., 2001. Inhibition of NFkappa
B activity by thalidomide through suppression of IkappaB kinase activity. J. Biol.
Chem. 276, 22382–22387.
Kim, Y.S., Kim, J.S., Jung, H.C., Song, I.S., 2004. The effect of thalidomide on the stimula-
tion of NF-kappaB activity and TNF-alpha production by lipopolysaccharide in a
human colonic epithelial cell line. Mol. Cells 17, 210–216.
Krutzik, S.R., Ochoa, M.T., Sieling, P.A., Uematsu, S., Ng, Y.W., Legaspi, A., Liu, P.T., Cole,
S.T., Godowski, P.J., Maeda, Y., Sarno, E.N., Norgard, M.V., Brennan, P.J., Akira, S.,
Rea, T.H., Modlin, R.L., 2003. Activation and regulation of Toll-like receptors 2
and 1 in human leprosy. Nat. Med. 9, 525–532.
Lee, S.B., Schorey, J.S., 2005. Activation andmitogen-activated protein kinase regulation
of transcription factors Ets and NF-kappa B in Mycobacterium-infected macro-
phages and role of these factors in tumor necrosis factor alpha and nitric oxide
synthase 2 promoter function. Infect. Immun. 73, 6499–6507.
Li, Q., Verma, I.M., 2002. NF-kappaB regulation in the immune system. Nat. Rev. Immunol.
2, 725–734.
Majumdar, S., Lamothe, B., Aggarwal, B.B., 2002. Thalidomide suppresses NF-kappa B
activation induced by TNF and H2O2, but not that activated by ceramide, lipopoly-
saccharides, or phorbol ester. J. Immunol. 168, 2644–2651.
Means, T.K., Jones, B.W., Schromm, A.B., Shurtleff, B.A., Smith, J.A., Keane, J., Golenbock,
D.T., Vogel, S.N., Fenton, M.J., 2001. Differential effects of a Toll-like receptor antag-
onist on Mycobacterium tuberculosis-induced macrophage responses. J. Immunol.
166, 4074–4082.
Moreira, A.L., Sampaio, E.P., Zmuidzinas, A., Frindt, P., Smith, K.A., Kaplan, G., 1993.
Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing
mRNA degradation. J. Exp. Med. 177, 1675–1680.Noman, A.S., Koide, N., Hassan, F., I-E-Khuda, I., Dagvadorj, J., Tumurkhuu, G., Islam, S.,
Naiki, Y., Yoshida, T., Yokochi, T., 2009. Thalidomide inhibits lipopolysaccharide
induced tumor necrosis factor-alpha production via down-regulation of MyD88
expression. Innate Immun. 15, 33–41.
Pathak, S.K., Basu, S., Bhattacharyya, A., Pathak, S., Kundu, M., Basu, J., 2005.Mycobacte-
rium tuberculosis lipoarabinomannan-mediated IRAK-M induction negatively regu-
lates Toll-like receptor-dependent interleukin 12p40 production in macrophages.
J. Biol. Chem. 280, 42794–42800.
Pathak, S.K., Basu, S., Basu, K.K., Banerjee, A., Pathak, S., Bhattacharyya, A., Kaisho, T.,
Kundu, M., Basu, J., 2007. Direct extracellular interaction between the early secret-
ed antigen ESAT-6 ofMycobacterium tuberculosis and TLR2 inhibits TLR signaling in
macrophages. Nat. Immunol. 8, 610–618.
Pereira, R.M., Calegari-Silva, T.C., Hernandez, M.O., Saliba, A.M., Redner, P., Pessolani,
M.C., Sarno, E.N., Sampaio, E.P., Lopes, U.G., 2005. Mycobacterium leprae induces
NF-kappaB-dependent transcription repression in human Schwann cells. Biochem.
Biophys. Res. Commun. 335, 20–26.
Raﬁee, P., Stein, D.J., Nelson, V.M., Otterson, M.F., Shaker, R., Binion, D.G., 2010. Thalid-
omide inhibits inﬂammatory and angiogenic activation of human intestinal micro-
vascular endothelial cells (HIMEC). Am. J. Physiol. Gastrointest. Liver Physiol. 298,
G167–176.
Ridley, D.S., Jopling, W.H., 1966. Classiﬁcation of leprosy according to immunity. A ﬁve-
group system. Int. J. Lepr. Other Mycobact. Dis. 34, 255–273.
Sampaio, E.P., Sarno, E.N., Galilly, R., Cohn, Z.A., Kaplan, G., 1991. Thalidomide selective-
ly inhibits tumor necrosis factor alpha production by stimulated human mono-
cytes. J. Exp. Med. 173, 699–703.
Sampaio, E.P., Kaplan, G., Miranda, A., Nery, J.A.C., Miguel, C.P., Viana, S.M., Sarno, E.N.,
1993. The inﬂuence of thalidomide on the clinical and immunological manifesta-
tion of erythema nodosum leprosum. J. Infect. Dis. 168, 408–414.
Sarno, E.N., Grau, G.E., Vieira, L.M., Nery, J.A., 1991. Serum levels of tumour necrosis
factor-alpha and interleukin-1 beta during leprosy reactional states. Clin. Exp.
Immunol. 84, 103–108.
Scollard, D.M., Joyce, M.P., Gillis, T.P., 2006. Development of leprosy and type 1 leprosy
reactions after treatment with inﬂiximab: a report of 2 cases. Clin. Infect. Dis. 43,
e19–22.
Teo, S.K., Resztak, K.E., Schefﬂer, M.A., Kook, K.A., Zeldis, J.B., Stirling, D.I., Thomas, S.D.,
2002. Thalidomide in the treatment of leprosy. Microbes Infect. 4, 1193–1202.
